novo nordisk lawsuit semaglutide Ozempic side effects can move forward Novo Nordisk's lawsuit on unoriginal

The rationale for this approach was to investigate if GLP-1 signalling could cause metabolic reprograming that would persist after removal of receptor stimulation (Fig

PlexusDx uses genetic testing as an optional add-on ($99 after your first month of treatment) to help tailor dosing strategies and identify which patients need long-term continuous coverage versus occasional maintenance approaches

By route of administration type, the injectable segment led the market with a 83% share in 2025

There are many ways you can reduce your risk of heart disease and promote heart health while living with diabetes (you can learn more ways here)

That's not a reason for alarm, but it is a reason coverage decisions and clinical guidelines will keep evolving as the data matures It would be critical to know whether chronic diseases that might be associated with obesity also show a gradual decline